BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

This review commemorates the 40th anniversary of DNA sequencing, a period in which we
have already witnessed multiple technological revolutions and a growth in scale from a few …

Thousands of pathogens are known to infect humans, but only a fraction are readily
identifiable using current diagnostic methods. Microbial cell-free DNA sequencing offers the …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Mutations, the fuel of evolution, are first manifested as rare DNA changes within a population
of cells. Although next-generation sequencing (NGS) technologies have revolutionized the …

Nucleosome positioning varies between cell types. By deep sequencing cell-free DNA
(cfDNA), isolated from circulating blood plasma, we generated maps of genome-wide in vivo …

Disclaimer: This statement is designed primarily as an educational resource for clinicians to
help them provide quality medical services. Adherence to this statement is completely …

Breast cancer is the most common cancer among women worldwide. Due to its complexity in
nature, effective breast cancer treatment can encounter many challenges. Traditional …

Biopsy, including tissue and liquid biopsy, offers comprehensive and real-time physiological
and pathological information for disease detection, diagnosis, and monitoring. Fluorescent …

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of
cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient …